Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4350326 | 1.00 | SLC6A9 (0.57) | SLC6A9MAPK1SLC6A3SLC6A2SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL4353935 | 0.90 | SLC6A9 (0.72) | SLC6A9 | |
| Trifluoroacetic Acid SCHEMBL2097212 | 0.90 | SLC6A9 (0.72) | SLC6A9 | |
| Trifluoroacetic Acid SCHEMBL2096878 | 0.90 | SLC6A9 (0.72) | SLC6A9 | |
| SCHEMBL2054723 | 0.87 | SLC6A9 (0.73) | SLC6A9 | |
| Trifluoroacetic Acid SCHEMBL2098754 | 0.82 | SLC6A9 (0.74) | SLC6A9 | |
| Trifluoroacetic Acid SCHEMBL4360720 | 0.82 | SLC6A9 (0.74) | SLC6A9 | |
| Trifluoroacetic Acid SCHEMBL4349938 | 0.82 | SLC6A9 (0.74) | SLC6A9 | |
| SCHEMBL2054716 | 0.79 | SLC6A9 (0.76) | SLC6A9 | |
| SCHEMBL4589243 | 0.73 | SLC6A9 (1.00) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286765-A1 | Therapeutic Agents | GRIA1, GRIN1, GLRA1 | SLC6A9 112/4885MAPK1 3276/4885SLC6A3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.